Maria Azucena Ramos
Family · Marrero, LANPI 1710146196
Payments from drug & device makers
Across 446 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novo Nordisk$994
- Xeris Pharmaceuticals, Inc.$774
- Boehringer Ingelheim$766
- Amgen$639
- AbbVie$536
- plus $4K from 30 others
What the payments were for
- Travel & lodging$1,44415%
- Food & beverage$8,36385%
- Education$370%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 45 | $2,261 |
| Novo Nordisk | 60 | $994 |
| Xeris Pharmaceuticals, Inc. | 45 | $774 |
| Boehringer Ingelheim | 39 | $766 |
| Amgen | 28 | $639 |
| AbbVie | 29 | $536 |
| Bayer | 30 | $535 |
| Lilly USA, LLC | 23 | $449 |
| Sanofi-aventis U.S. LLC | 18 | $367 |
| Dexcom, Inc. | 18 | $332 |
| Abbott | 14 | $316 |
| Amneal Pharmaceuticals LLC | 27 | $297 |
| Corcept Therapeutics | 9 | $263 |
| Merck | 11 | $173 |
| Averitas Pharma Inc. | 2 | $168 |
| AstraZeneca(2 entities) | 8 | $168 |
| Esperion Therapeutics, Inc. | 7 | $123 |
| Novartis | 5 | $105 |
| Pfizer | 3 | $67 |
| Ascendis Pharma Endocrinology Inc | 3 | $66 |
| GRT US Holding, Inc. | 3 | $62 |
| Amarin Pharma, Inc. | 2 | $46 |
| Recordati_rare_diseases_inc. | 2 | $42 |
| IBSA Pharma Inc. | 2 | $40 |
| Sequel Med Tech, LLC | 1 | $35 |
| Johnson & Johnson | 2 | $27 |
| Almatica Pharma LLC | 1 | $26 |
| Neurocrine Biosciences, Inc. | 1 | $25 |
| Rhythm Pharmaceuticals, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Amryt Pharma Holdings Ltd | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Cequr Corporation | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,122
- Qutenza$146
- EVENITY$120
How this compares
$9,844 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $228,333 |
| MounjaroTirzepatide | 49 | $89,066 |
| JardianceEmpagliflozin | 73 | $85,827 |
| TrulicityDulaglutide | 22 | $38,349 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $28,388 |
| TradjentaLinagliptin | 22 | $26,646 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $18,507 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $14,491 |
| JanuviaSitagliptin Phosphate | 13 | $12,216 |
| FarxigaDapagliflozin Propanediol | 12 | $10,457 |
| Gvoke Hypopen 2-PackGlucagon | 14 | $9,122 |
| SynthroidLevothyroxine Sodium | 83 | $8,846 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $6,848 |
| Novolog FlexpenInsulin Aspart | 12 | $4,151 |
| HumalogInsulin Lispro | 12 | $3,303 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $994 | $228,333139 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $449 | $130,71983 claims |
| Boehringer IngelheimJardiance, Tradjenta | $766 | $112,47395 claims |
| MerckJanuvia | $173 | $12,21613 claims |
| AstraZenecaFarxiga | $168 | $10,45712 claims |
| AbbVieSynthroid | $536 | $8,84683 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $297 | $2,30594 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.
Other family in Marrero
- Sharon JacksonMarrero$13K
- Jolie MontreuilMarrero$13K
- Rebecca EzellSlidell$268K
- Erin PierceNew Orleans$261K
- Tavell KindallNew Orleans$194K
- Ashlea HillRuston$169K
- Brittany MillerVille Platte$158K
- Ryanne ClarkeGretna$123K
- Elidia DewittBaton Rouge$108K
- Rebekah GarrardLafayette$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.